Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the
assessment of early response to therapy by minimal residual disease (MRD) monitoring has …

Abstract Minimal (or 'measurable') residual disease in acute lymphoblastic leukemia
appears to be a prognostic indicator, with potential value in informing individualized …

The combination of ponatinib, a third‐generation BCR:: ABL1 tyrosine kinase inhibitor, with
hyper‐CVAD chemotherapy resulted in high rates of complete molecular remissions and …

The standard treatment for adults with Philadelphia chromosome–positive (Ph+) acute
lymphoblastic leukemia (ALL) in Japan is imatinib-based chemotherapy followed by …

Background This meta-analysis was performed to explore the impact of minimal residual
disease (MRD) prior to transplantation on the prognosis for patients with acute lymphoblastic …

This study evaluated the effects of pretransplantation minimal residual disease (pre‐MRD)
on outcomes of patients with acute lymphoblastic leukemia (ALL) who underwent …

To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI)
administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive …

In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia
patients were treated with chemotherapy for induction and consolidation, followed by …

Abstract The Japan Adult Leukemia Study Group (JALSG) Ph+ ALL202 study reported a
high complete remission (CR) rate for Philadelphia chromosome-positive acute …

Abstract Purpose of Review Measurable residual disease (MRD) is an important monitoring
parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL) …